冠昊生物(300238) - 2024 Q1 - 季度财报

Financial Performance - Revenue for Q1 2024 was CNY 91,441,252.36, a decrease of 18.85% compared to CNY 112,684,910.79 in the same period last year[5] - Net profit attributable to shareholders was CNY 14,391,514.75, down 34.92% from CNY 22,115,265.70 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 91,441,252.36, a decrease of 18.8% compared to CNY 112,684,910.79 in Q1 2023[19] - Net profit for Q1 2024 was CNY 15,474,779.84, a decline of 35.8% from CNY 24,073,789.17 in Q1 2023[20] - The company reported a basic and diluted earnings per share of CNY 0.05 for Q1 2024, compared to CNY 0.08 in Q1 2023[21] - Total operating costs for Q1 2024 were CNY 71,751,172.33, down 17.6% from CNY 87,034,936.18 in the previous year[19] Cash Flow and Liquidity - Operating cash flow increased by 27.78% to CNY 10,870,539.98, compared to CNY 8,507,031.19 in Q1 2023[5] - The company’s cash flow from operating activities showed a significant improvement, indicating better liquidity management[20] - Total cash inflow from operating activities is ¥99,050,081.27, down 2.9% from ¥101,952,290.69 in the previous period[22] - Cash outflow from operating activities decreased to ¥88,179,541.29 from ¥93,445,259.50, reflecting a reduction of 5.6%[22] - The net cash flow from operating activities for the current period is ¥10,870,539.98, an increase of 27.8% compared to ¥8,507,031.19 in the previous period[22] - Cash inflow from financing activities is ¥24,000,000.00, with a net cash flow of ¥15,790,316.69, compared to -¥2,989,717.62 in the previous period[24] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 692,367,956.43, reflecting a 2.03% increase from CNY 678,594,899.40 at the end of the previous year[5] - The total non-current assets amounted to CNY 417,526,458.27, an increase from CNY 411,317,030.68 in the previous year[17] - Total liabilities decreased slightly to CNY 220,713,856.77 in Q1 2024 from CNY 222,334,653.65 in Q1 2023[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 31,938[10] - The top shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., holds 20.76% of the shares, totaling 55,044,822 shares[11] - The second-largest shareholder, Beijing Century Tianfu Venture Capital Center, holds 5.80% of the shares, totaling 15,366,266 shares[11] - The company is actively managing its shareholder structure, with notable participation in financing and securities lending activities by major shareholders[11] Investment and Expenses - Cash flow from investing activities showed a net outflow of CNY 34,622,805.36, a 505.84% increase in outflow compared to CNY -5,714,848.55 in the previous year[8] - Research and development expenses for Q1 2024 were CNY 7,484,200.53, down from CNY 9,567,734.69 in Q1 2023, reflecting a 21.8% reduction[19] - The company invested ¥34,622,805.36 in fixed assets, a substantial increase from ¥5,725,426.55 in the previous period[24] Other Financial Metrics - The weighted average return on equity decreased to 2.73% from 4.45% year-on-year[5] - Other income decreased by 59.14% to CNY 1,218,321.80, primarily due to reduced government subsidies[7] - The company paid ¥34,795,280.36 in employee compensation, slightly increasing from ¥34,406,341.98[22] - Tax payments increased significantly to ¥7,257,699.29 from ¥2,900,501.76, marking a rise of 150.5%[22] Inventory and Receivables - Accounts receivable increased to ¥74,827,102.21 from ¥61,142,630.83, showing a growth of about 22.4%[15] - The company reported a significant increase in accounts receivable, which may indicate improved sales performance or extended credit terms[15] - Prepayments rose to ¥10,086,994.43 from ¥7,215,658.54, indicating an increase of approximately 39.5%[15] - Inventory decreased to ¥68,970,276.51 from ¥71,601,478.41, reflecting a decline of about 3.6%[15] - Total current assets increased to ¥274,841,498.16 from ¥267,277,868.72, marking a growth of approximately 2.1%[15] Corporate Actions - The company has extended the validity period for the issuance of A-shares to specific investors by 12 months, maintaining other terms unchanged[13] - The company has not yet audited the first quarter report[25]